Sales & Marketing At BIO 2024, an industry vows to reclaim its narrative At BIO2024 experts agreed that in a period where pharma is deeply unpopular, the industry must be proactive in telling its story.
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.